Formula (I) Compounds for Selective Persistent Sodium Current Blockade

Solution Overview

Problem

Current antiepileptic drugs targeting sodium channels suffer from severe toxicity at therapeutic doses, compromising physiological neuronal function and lacking selectivity for persistent sodium current, necessitating improved therapeutic options with enhanced efficacy and tolerability for treating neurological disorders associated with excessive neuronal excitability and sodium channel mutations.

Innovation Solution

Development of compounds of Formula (I) and their pharmaceutically acceptable salts, which preferentially inhibit persistent sodium current over peak sodium current, administered in specific doses to treat conditions like epilepsy and encephalopathies, reducing seizure frequency and severity without causing adverse effects such as ataxia, lethargy, or vomiting.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If standard NaV-targeting AEDs (carbamazepine, oxcarbazepine, phenytoin) are used to block peak INa, then neuronal excitability is reduced, but severe toxicity occurs including ataxia, lethargy, vomiting, and seizures

Engineering Contradiction:

Improveseizure controlVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing compounds that selectively target persistent sodium current (INaL) rather than peak sodium current. This selective inhibition allows the drug to act on the specific pathological current responsible for seizures while preserving the physiological peak current necessary for normal neuronal function, thereby achieving seizure control without the severe toxicity seen with standard AEDs

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by modifying the chemical structure of sodium channel blockers to achieve differential binding kinetics and selectivity. The compounds of Formula (I) are designed with specific molecular features that allow them to preferentially bind to and inhibit the persistent current state of the sodium channel, changing the pharmacological parameters of sodium channel interaction to improve therapeutic index

Inventive Principle:

Principle #35Parameter changes

2Reliability

If NaV-targeting AEDs inhibit both peak INa and persistent INa at therapeutic concentrations, then seizure activity is reduced, but excessive peak INa inhibition compromises physiological neuronal activity

Engineering Contradiction:

Improveseizure freedomVSAvoidphysiological function

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent applies local quality by designing compounds that selectively target persistent sodium current (INaL) rather than peak sodium current. This selective inhibition allows the drug to act on the specific pathological current responsible for seizures while preserving the physiological peak current necessary for normal neuronal function, thereby achieving seizure control without compromising physiological neuronal activity

Inventive Principle:

Principle #3Local quality

3Reliability

If current AEDs are used to treat genetic epilepsy caused by SCN1A, SCN2A, or SCN8A mutations, then some seizure control is achieved, but tolerability is poor due to off-target activities and excessive peak INa inhibition

Engineering Contradiction:

Improveseizure controlVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing compounds that selectively target persistent sodium current (INaL) rather than peak sodium current. This selective inhibition allows the drug to act on the specific pathological current responsible for seizures while preserving the physiological peak current necessary for normal neuronal function, thereby achieving seizure control without the severe toxicity seen with standard AEDs

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs intermediary by using a selective persistent current blocker as a mediator between the pathological gain-of-function mutations and therapeutic seizure control. The compounds of Formula (I) serve as an intermediary mechanism that specifically counteracts the abnormal persistent current generated by SCN1A, SCN2A, or SCN8A mutations without interfering with normal peak current-mediated neuronal signaling

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds effectively reduce seizure frequency and severity in neurological disorders by selectively targeting persistent sodium current, offering improved tolerability and efficacy compared to standard antiepileptic drugs, with reduced side effects.

Implementation Method 1

Their blockade, and consequent inhibition of neuronal sodium current (INa), is ideally positioned to reduce excitability

Methodology Applied

Scientific EffectSodium channel blockade: Conduction (electrical)

Data Source

PatentUS20250312338A1Treatment of neurological disorders

Publication Date: 2025.10.09 PRAXIS PRECISION MEDICINES INC

AI summary

The present disclosure is generally directed to methods of treating a disease, disorder, or condition, e.g., a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with de novo gain-of-function or loss-of-function mutations in major central nervous system sodium channel genes, such as for example, SCN1A, SCN2A, and SCN8A, using a compound of Formula (I) as defined herein or a pharmaceutically acceptable salt thereof.